Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

PCORI to Study More Head-to-Head Comparisons in 2014

January 27, 2014

At a conference last week, Patient-Centered Outcomes Research Institute (PCORI) Executive Director Dr. Joe Selby announced plans to fund more comparative effectiveness research (CER) examining head-to-head treatment alternatives. While such research could help patients understand what treatments work best for specific conditions, the National Pharmaceutical Council (NPC) cautioned that the research topics and processes should be meaningful, prioritized and transparent.

NPC has previously noted that PCORI’s research should “focus on conditions with a high burden of illness and cost such as chronic diseases and provide evidence that will facilitate good decision-making by health care professionals and patients.” In addition, the research “should encompass all health care services, including devices, diagnostics, health care delivery methods, pharmaceuticals and medical and surgical procedures, and establish priorities for research in an explicit and transparent manner.” It is unclear what research projects PCORI plans to prioritize and fund in 2014, but Dr. Selby has acknowledged that fewer of those projects will be investigator-initiated.

NPC pointed out that much is already known about how drugs work, but less is known about treatment alternatives, such as medication vs. surgery, imaging vs. CT scans or treatment provided by a specialist vs. a primary care doctor.

“CER is much more than a ‘red pill vs. blue pill’ equation,” said NPC President Dan Leonard. “Meaningful CER will consider a broad range of treatment options as well as individual patient outcomes. And while PCORI has acknowledged the need to conduct research that takes these individual treatment effects into account, we hope that will be the case with any head-to-head comparisons they decide to fund.”  

With respect to head-to-head comparisons, Leonard added that these types of assessments should be rooted in the real world and take into account biological variations, socio-economic factors and patient preferences when navigating decisions around treatment options. Whether the choice is among medications, surgery, medical devices, lifestyle changes or other treatment approaches, it is possible for CER to reflect the variability inherent in treating individuals rather than populations.

As NPC has pointed out in previous research, if CER is used to simply determine what works best on average, we may lose sight of what works best for individuals. This could lead to coverage and/or reimbursement decisions being made based on this information, which could result in poorer health outcomes and increased health care costs.

The reason for this is also simple—those patients who do not respond to the average treatment could end up costing more to treat if access is limited to other treatments that work better for them. Even if these patients are granted access to a second treatment, they likely will be forced to pay a higher copayment. For some patients, this could delay access to treatments that are deemed most effective for their condition.

“Patient differences matter a great deal. PCORI has an important role to play in funding meaningful research that answers questions patients care about,” said Leonard. “That’s why we hope that PCORI will continue to be thoughtful in its approach to funding research and engaging the entire research community in its efforts.”

Blog Post

Are We Getting the Right Data to Make Individualized Health Decisions? Maybe.

Personalized medicine—an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each...
Blog Post

CER Tweets of the Week: AHCJ CER Fellowships Announced; Latest Issue of JCER Published (August 8-12)

Last week, comparative effectiveness research stakeholders tweeted about the announcement of this year’s Association of Health Care Journalists CER...
Blog Post

CER Tweets of the Week: EBM in Elite Sports; Clinical Nuances (August 1 – August 5)

Last week, comparative effectiveness research stakeholders tweeted about a blog post published in BMJ (@BJSM_BMJ) that discusses the use of evidence...
Blog Post

CER Tweets of the Week: PCORI Gives $153 Million in Grants, ACO Use of Preventative Services (July 18 – July 22)

What were comparative effectiveness research stakeholders buzzing about last week? Among other topics, they tweeted that the Patient-Centered...
Press Release

Data Can Offer Critical Insights, But Roadblocks to Data Access Persist

(Washington, D.C., April 1, 2016)—Data is key to improving health outcomes and creating efficiencies in our health care system, but a new study...
Press Release

Fit for Purpose? New NPC, AcademyHealth Framework Closes Gaps Between Payer Needs and Research Answers

(Washington, DC, September 21, 2015)—Despite multi-million dollar public and private investments to tap into big data and improve the evidence...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Commentary and Testimony Page

NPC Comments on Revised PCORI Methodology Standards

March 28, 2016Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036 Dr. Robin...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
YouTube Videos

When Is Evidence Fit for Purpose? Closing Gaps Between Researchers, Payers

Despite multi-million dollar public and private investments to tap into big data and improve the evidence available for health care decision-making,...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
Blog Post

Are We Getting the Right Data to Make Individualized Health Decisions? Maybe.

Personalized medicine—an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each...
Blog Post

CER Tweets of the Week: AHCJ CER Fellowships Announced; Latest Issue of JCER Published (August 8-12)

Last week, comparative effectiveness research stakeholders tweeted about the announcement of this year’s Association of Health Care Journalists CER...
Blog Post

CER Tweets of the Week: EBM in Elite Sports; Clinical Nuances (August 1 – August 5)

Last week, comparative effectiveness research stakeholders tweeted about a blog post published in BMJ (@BJSM_BMJ) that discusses the use of evidence...
Blog Post

CER Tweets of the Week: PCORI Gives $153 Million in Grants, ACO Use of Preventative Services (July 18 – July 22)

What were comparative effectiveness research stakeholders buzzing about last week? Among other topics, they tweeted that the Patient-Centered...

Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges

This study provides an early evaluation of the CER Collaborative's training program's impact on...

Data, Data Everywhere, But Access Remains a Big Issue for Researchers

This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded...
cersurvey16

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the...
  •  
  • 1 of 15
  • >